Effects of Mefloquine on Ca2+ Uptake and Release by Dog Brain Microsomes

Archives Internationales de Pharmacodynamie et de Therapie

Volumn 331, Issue 3, 1996, Pages 221-231

  Lee, H S ^a   Go, M L ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MEFLOQUINE; QUININE; ANTIMALARIAL AGENT; CALCIUM; INOSITOL 1,4,5 TRISPHOSPHATE;

ANIMAL CELL; ARTICLE; BRAIN; CALCIUM CELL LEVEL; CONTROLLED STUDY; DOG; MALARIA; MICROSOME; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ANIMALS; ANTIMALARIALS; BRAIN; CALCIUM; DOGS; INOSITOL 1,4,5-TRISPHOSPHATE; MEFLOQUINE; MICROSOMES; QUININE;

EID: 0030300168     PISSN: 00039780     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. BEM, J. L., KERR, L. and STUERCHLER, D. Mefloquine prophylaxis: An overview of spontaneous reports of severe psychiatric reactions and convulsions. J. trop. med. Hyg. 95, 167-179 (1992).
2. BERRIDGE, M. J. and IRVINE, R. F. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature, Lond. 312, 315-321 (1984).
3. BEZPROZVANNY, I. B., ONDRIAS, K., KAFTAN, E., STOYANOVSKY, D. A. and EHRLICH, B. E. Activation of the calcium release channel (ryanodine receptor) by heparin. Molec. Biol. Cell 4, 347-352 (1993).
4. DANOFF, S. K. and ROSS, C. A. The inositol triphosphate receptor gene family: Implications for normal and abnormal brain function. Progr. Neuropsychopharmacol. biol. Psychiat. 18, 1-16 (1994).
5. EL BENNA, J., HAKIM,.J. and LABRO, M.-T. Inhibition of human neutrophil protein kinase C activity by the antimalarial drug mefloquine. Biochem. Pharmacol. 43, 527-532 (1992).
6. FRANSSEN, G., ROUVEIX, B., LEBRAS, J., BAUCHET, J., VERDIER, F., MICHON, C. and BRICAIRE, F. Divided dose kinetics of mefloquine in man. Brit. J. clin. Pharmacokin. 15, 179-184 (1989).
7. 4 binding in Alzheimer's disease brain. Brain Res. 681, 160-166 (1995).
8. 2+ uptake by crude microsomes of rabbit skeletal muscle. Arch. int. Pharmacodyn. 329, 255-271 (1995).
9. ISHIMA, Y., FUJIMAGARI, M., MASUZAWA, Y. and WAKU, K. Inositol 1,4,5-triphosphate accumulation in brain of lithium-treated rats. Lipids 28, 577-581 (1993).
10. LOWRY, O. H., ROSEBROUGH, N. J., PARR, A. J. and RANDALL, R. J. Protein measurement with Folin phenol reagent. J. biol. Chem. 193, 265-275 (1951).
11. MATSUMOTO, M., NAKAGAWA, T., INOUE, T., NAGATA, E., TANAKA, K., TAKANO, H., MINOWA, O., KUNO, J., SAKAKIBARA, S., YAMAUA, M., YONESHIMA, H., MIYAWAKI, A., FUKUUCHI, Y., FURUICHI, T., OKANO, H., MIKOSHIBA, K. and NODA, T. Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-triphosphate receptor. Nature 379, 168-171 (1996).
12. MU, J. Y., ISRAILI, H. and DAYTON, P. G. Studies of the disposition and metabolism of mefloquine HCl (WR 142,490), a quinolinemethanol antimalarial in the rat. Drug Metab. Disp. 3, 198-210 (1975).
13. OGWANG, R., MWANGI, J., GACHIHI, G., NWACHUKWU, A., ROBERTS, C. R. and MARTIN, S. K. Use of pharmacological agents to implicate a role for phosphoinositide hydrolysis products in malaria gamete formation. Biochem. Pharmacol. 46, 1601-1606 (1993).
14. 2+ release from intracellular membrane systems. Molec. Pharmacol. 36, 673-680 (1989a).
15. + channel blockers. Molec. Pharmacol. 36, 664-672 (1989b).
16. PALMER, K. J., HOLLIDAY, S. M. and BROGEN, R. N. Mefloquine: A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 45, 430-475 (1993).
17. 2+ flux. Cell. Signal. 6, 561-567 (1994).
18. TAYLOR, C. W. and RICHARDSON, A. Structure and function of inositol triphosphate receptors. Pharmacol. Ther. 51, 97-137 (1991).